Liver Transplantation and Mean Pulmonary Artery Pressure

by Phyllis Hanlon, Contributing Writer People with liver disease can develop a type of pulmonary hypertension (PH – high blood pressure in the lungs) called portopulmonary hypertension (POPH). POPH involves increased blood pressure and resistance in the arteries of the lungs in people who also have high blood pressure in the veins of the liver

September 20th, 2017|

Genetic Counseling and Testing May Provide Benefits for Patients With PAH

by Phyllis Hanlon, Contributing Writer Genetic testing is becoming more common for patients with certain medical conditions. For instance, cardiologists now refer patients more frequently for genetic testing to find out if they are at risk for an underlying heart condition. Although practice guidelines suggest that pulmonologists and others who treat patients with pulmonary arterial

September 14th, 2017|

CTEPH: Under-Diagnosed and Under-Treated

by Phyllis Hanlon, Contributing Writer Scientists continue to explore the origins and effects of WHO Group 4 PH (CTEPH, chronic thromboembolic pulmonary hypertension), but much more research needs to be conducted before the disease is fully understood. A study published in the European Respiratory Review (http://err.ersjournals.com/content/26/143/160121) reported that CTEPH is thought to occur as a

August 31st, 2017|

Workshop Explores a Precision Medicine Approach to Pulmonary Vascular Disease

by Phyllis Hanlon, Contributing Writer The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) and Cardiovascular Medical Research and Education Fund (CMREF) co-sponsored a workshop to look at  better ways to treat pulmonary vascular disease (PVD) through precision medicine. Precision medicine, which is sometimes referred to as personalized medicine,

August 18th, 2017|

Holistic Approach Helps Patients Engage in Care

by Phyllis Hanlon, Contributing Writer Recent advances and clinical research have shown that better care for people with pulmonary arterial hypertension (PAH) can lead to longer lives. But recently the focus has shifted from treatment options that improve the functional aspects of the disease alone to including care that improves overall quality of life

August 2nd, 2017|

Report Provides Insight into PAH Linked in Some Parts of the World to a Parasite

by Phyllis Hanlon, Contributing Writer Schistosomiasis, a disease caused by infection with freshwater parasitic worms belonging to the genus Schistosoma, is one of the most prevalent parasitic infections in the world. The Global Network reports that approximately 240 million people in 78 countries, with the greatest impact in Africa, are infected with this parasite.

July 27th, 2017|

Study Looks at Future Directions in CTEPH Patient Care

by Phyllis Hanlon, Contributing Writer In 1967, doctors performed the first pulmonary endarterectomy (PEA) (also known as pulmonary thromboendarterectomy or PTE) – surgery to remove old blood clots from the pulmonary arteries. This operation continues to be the first recommended treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH), since it can potentially reduce or

June 28th, 2017|

With Addition of Two Sites, U.S. Patients Have Access to Care from 52 PHA-Accredited Health Care Facilities

Silver Spring, Md. (June 21, 2017) - With the addition of two newly Pulmonary Hypertension Association (PHA)-accredited health care sites, more U.S. patients have access to care from facilities that have completed a rigorous review process for providing specialized pulmonary hypertension (PH) care. The University of New Mexico School of Medicine PH Program in

June 22nd, 2017|